Human immunodeficiency virus is a driven factor of human papilloma virus among women: evidence from a cross-sectional analysis in Yaoundé, Cameroon.
Adult
Alphapapillomavirus
/ genetics
CD4 Lymphocyte Count
Cameroon
/ epidemiology
Coinfection
/ virology
Cross-Sectional Studies
DNA, Viral
/ genetics
Female
Genotype
HIV Infections
/ complications
HIV-1
/ genetics
Humans
Papillomavirus Infections
/ epidemiology
Uterine Cervical Neoplasms
/ prevention & control
Viral Load
HIV
HPV
Women
Yaoundé
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
19 05 2020
19 05 2020
Historique:
received:
02
01
2020
accepted:
07
05
2020
entrez:
21
5
2020
pubmed:
21
5
2020
medline:
10
2
2021
Statut:
epublish
Résumé
Human papillomavirus (HPV) is the leading cause of cervical cancers, causing 270.000 deaths annually worldwide of which 85% occur in developing countries with an increasing risk associated to HIV infection. This study aimed at comparing HPV's positivity and genotype distribution in women according to their HIV status and determinants. A comparative study was carried out in 2012 at the Chantal BIYA International Reference Centre (CIRCB) among 278 women enrolled consecutively at the General Hospital and the Gynaeco-Obstetric and Paediatric Hospital of the City of Yaoundé. HPV genotyping was performed by real-time PCR, HIV serological screening by serial algorithm, CD4 T cell phenotyping by flow cytometry and HIV viral load by Abbott m2000RT. Statistical analyses were performed using Microsoft Excel 2016 and Graph Pad version 6.0 software; with P < 0.05 considered statistically significant. Globally, mean age was 37 ± 3 years; median CD4-count for HIV+ was 414 cells/mm In Yaoundé, HPV rate appear to be very high, with higher rates of genotypes other than 16 and 18. In the event of HIV infection, the risk of HPV positivity is two times higher, favoured essentially by immunodeficiency. Thus, HIV-infected women should be closely monitored to prevent the emergence of cervical cancer.
Sections du résumé
BACKGROUND
Human papillomavirus (HPV) is the leading cause of cervical cancers, causing 270.000 deaths annually worldwide of which 85% occur in developing countries with an increasing risk associated to HIV infection. This study aimed at comparing HPV's positivity and genotype distribution in women according to their HIV status and determinants.
METHODS
A comparative study was carried out in 2012 at the Chantal BIYA International Reference Centre (CIRCB) among 278 women enrolled consecutively at the General Hospital and the Gynaeco-Obstetric and Paediatric Hospital of the City of Yaoundé. HPV genotyping was performed by real-time PCR, HIV serological screening by serial algorithm, CD4 T cell phenotyping by flow cytometry and HIV viral load by Abbott m2000RT. Statistical analyses were performed using Microsoft Excel 2016 and Graph Pad version 6.0 software; with P < 0.05 considered statistically significant.
RESULTS
Globally, mean age was 37 ± 3 years; median CD4-count for HIV+ was 414 cells/mm
CONCLUSION
In Yaoundé, HPV rate appear to be very high, with higher rates of genotypes other than 16 and 18. In the event of HIV infection, the risk of HPV positivity is two times higher, favoured essentially by immunodeficiency. Thus, HIV-infected women should be closely monitored to prevent the emergence of cervical cancer.
Identifiants
pubmed: 32430034
doi: 10.1186/s12985-020-01340-y
pii: 10.1186/s12985-020-01340-y
pmc: PMC7236111
doi:
Substances chimiques
DNA, Viral
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
69Références
Urologia. 2014 Oct-Dec;81(4):200-8
pubmed: 25532465
J Cancer Epidemiol. 2011;2011:319872
pubmed: 22007216
Oncol Lett. 2017 Dec;14(6):7629-7635
pubmed: 29344211
APMIS. 2014 Aug;122(8):667-73
pubmed: 25046198
Science. 2006 Dec 8;314(5805):1603-6
pubmed: 17158329
BMC Infect Dis. 2014 Oct 30;14:551
pubmed: 25927224
Ann Intern Med. 2003 Mar 18;138(6):453-9
pubmed: 12639077
Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):101-6
pubmed: 11219765
PLoS Med. 2006 Nov;3(11):e442
pubmed: 17132052
J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):390-9
pubmed: 22820809
Int J STD AIDS. 2014 Mar;25(3):163-77
pubmed: 24216030
J Clin Virol. 2005 Apr;32(4):278-85
pubmed: 15780805
Int J Cancer. 2004 Aug 20;111(2):278-85
pubmed: 15197783
PLoS One. 2011 Feb 17;6(2):e14705
pubmed: 21379574
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Medicine (Baltimore). 2018 Apr;97(14):e9545
pubmed: 29620669
Am J Obstet Gynecol. 2004 May;190(5):1241-8
pubmed: 15167825
PLoS One. 2017 Jan 6;12(1):e0168133
pubmed: 28060843
AIDS. 1990 Feb;4(2):107-12
pubmed: 2328092
J Natl Cancer Inst Monogr. 2003;(31):20-8
pubmed: 12807941
Am J Obstet Gynecol. 2015 May;212(5):606.e1-8
pubmed: 25499260
Lancet Oncol. 2010 Nov;11(11):1048-56
pubmed: 20952254
Infect Dis Obstet Gynecol. 2006;2006 Suppl:40470
pubmed: 16967912
J Infect Dis. 2010 Dec 15;202(12):1789-99
pubmed: 21067372
J Transl Med. 2009 Dec 18;7:108
pubmed: 20021658
PLoS One. 2019 Jun 3;14(6):e0217486
pubmed: 31158254
PLoS One. 2017 Nov 15;12(11):e0187928
pubmed: 29141014
Int J Cancer. 2006 Jun 15;118(12):3030-44
pubmed: 16404738
Otolaryngol Clin North Am. 2012 Aug;45(4):807-22
pubmed: 22793854
Med Trop (Mars). 2008 Dec;68(6):617-20
pubmed: 19639831